COMPARATIVE EVALUATION OF TACROLIMUS 0.03% OINTMENT VS OLOPATADINE 0.2% EYE DROPS IN THE TREATMENT OF VERNAL KERATOCONJUNCTIVITIS

Código QR

COMPARATIVE EVALUATION OF TACROLIMUS 0.03% OINTMENT VS OLOPATADINE 0.2% EYE DROPS IN THE TREATMENT OF VERNAL KERATOCONJUNCTIVITIS

Objective: To compare the efficacy of tacrolimus 0.03% ointment to olopatadine 0.2% eye drops in the treatment of vernal keratoconjunctivitis. Study Design: Prospective cross-sectional study. Place and Duration of Study: Eye Department Combined Military Hospital Quetta, from Feb to Jul 2019....

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hassan Sajjad Rathore, Shahzad Saeed, M. Ahsan Mukhtar, Umar Ijaz, Asad Habib, Iqra Ghaus
Formato:	article
Lenguaje:	EN
Publicado:	Army Medical College Rawalpindi 2021
Materias:	vernal keratoconjunctivitis tacrolimus olopatadine Medicine R Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/fb9a8d47b3b7483183731ea49a9c696e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Efficacy and safety of low-dose topical tacrolimus in vernal keratoconjunctivitis
por: Shoughy SS, et al.
Publicado: (2016)

Is Interferon α-2b 1 MillionIU/mL Truly Better Than Tacrolimus 0.03% for Steroid-Resistant VKC ?: Our 2-Year Experience at a Tertiary Health-Care Centre
por: Gupta S, et al.
Publicado: (2021)

Vernal keratoconjunctivitis
por: Addis H, et al.
Publicado: (2018)

Effect of topical Mitomycin-C (0.01%) in treatment of severe vernal refractory keratoconjunctivitis
por: SMH Emad, et al.
Publicado: (2005)

Eye drop emulsion containing 0.1% cyclosporin (1 mg/mL) for the treatment of severe vernal keratoconjunctivitis: an evidence-based review and place in therapy
por: Nebbioso M, et al.
Publicado: (2019)

Sequential Keraring implantation and corneal cross-linking for the treatment of keratoconus in children with vernal keratoconjunctivitis
por: Abozaid MA
Publicado: (2017)

Pharmacokinetics and safety of olopatadine hydrochloride 0.77% in healthy subjects with asymptomatic eyes: data from 2 independent clinical studies
por: Meier E, et al.
Publicado: (2017)

Efficacy of 0.05% epinastine and 0.1% olopatadine for allergic conjunctivitis as seasonal and preseasonal treatment
por: Mizoguchi T, et al.
Publicado: (2017)

Pooled analysis of two studies evaluating efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis
por: McLaurin E, et al.
Publicado: (2017)

Comparison of 0.2% and 0.18% hyaluronate eye drops in patients with moderate to severe dry eye with keratitis or keratoconjunctivitis
por: Groß D, et al.
Publicado: (2017)

Clinical and allergological analysis of ocular manifestations of sick building syndrome
por: Saeki Y, et al.
Publicado: (2017)

Epidemic Keratoconjunctivitis-Causing Adenoviruses Induce MUC16 Ectodomain Release To Infect Ocular Surface Epithelial Cells
por: Balaraj B. Menon, et al.
Publicado: (2016)

Impact of topical bimatoprost 0.01% and bimatoprost 0.03% on conjunctival irritation in rabbits
por: Abayomi B Ogundele, et al.
Publicado: (2010)

Management of Adenoviral Keratoconjunctivitis: Challenges and Solutions
por: Labib BA, et al.
Publicado: (2020)

Human kidney organoids model the tacrolimus nephrotoxicity and elucidate the role of autophagy
por: Jin Won Kim, et al.
Publicado: (2021)

Managing refractory glaucoma with a fixed combination of bimatoprost (0.03%) and timolol (0.5%)
por: Moataz E Gheith, et al.
Publicado: (2008)

Nicotine exacerbates tacrolimus-induced renal injury by programmed cell death
por: Yu Ji Jiang, et al.
Publicado: (2021)

Si0.97Ge0.03 microelectronic thermoelectric generators with high power and voltage densities
por: Ruchika Dhawan, et al.
Publicado: (2020)

Aqueous humor penetration of topical bimatoprost 0.01% and bimatoprost 0.03% in rabbits: response to authors
por: Chang-Lin J-E, et al.
Publicado: (2011)

Tacrolimus for the management of psoriasis: clinical utility and place in therapy
por: Malecic N, et al.
Publicado: (2016)

Preservative-free bimatoprost 0.03%/timolol 0.5% fixed combination in patients with glaucoma in clinical practice
por: Pfennigsdorf S, et al.
Publicado: (2016)

A Review of Topical Cyclosporine A Formulations—A Disease-Modifying Agent for Keratoconjunctivitis Sicca
por: Jerkins GW, et al.
Publicado: (2020)

Effects of treatment with bimatoprost 0.03% for 3 years in patients with normal-tension glaucoma
por: Inoue K, et al.
Publicado: (2014)

Preclinical Efficacy Comparison of Cyclosporine Ophthalmic Solution 0.09% vs Cyclosporine Ophthalmic Emulsion 0.05% vs Ciclosporin Ophthalmic Emulsion 0.1% in a NOD Mouse Model of Dry Eye Disease
por: Burade V, et al.
Publicado: (2020)

Clinical and virological analysis of epidemic keratoconjunctivitis caused by adenovirus type 54 in a regional ophthalmic clinic in Kyushu, Japan
por: Uemura T, et al.
Publicado: (2018)

Combination of hydrotropic nicotinamide with nanoparticles for enhancing tacrolimus percutaneous delivery
por: Pan W, et al.
Publicado: (2016)

Phase 3 Efficacy (Worse-Eye Analysis) and Long-Term Safety Evaluation of OTX-101 in Patients with Keratoconjunctivitis Sicca
por: Sheppard J, et al.
Publicado: (2021)

Efficacy and safety of fixed-combination travoprost 0.004%/timolol 0.5% in patients transitioning from bimatoprost 0.03%/timolol 0.5% combination therapy
por: Schnober D, et al.
Publicado: (2015)

Application of quasi-emulsification and modified double emulsification techniques for formulation of tacrolimus microsponges
por: Zaman M, et al.
Publicado: (2018)

Variability of Tacrolimus Trough Concentration in Liver Transplant Patients: Which Role of Inflammation?
por: Anaelle Chavant, et al.
Publicado: (2021)

Enhanced dissolution and oral absorption of tacrolimus by supersaturable self-emulsifying drug delivery system
por: Lee DR, et al.
Publicado: (2016)

Bimatoprost 0.01% or 0.03% in patients with glaucoma or ocular hypertension previously treated with latanoprost: two randomized 12-week trials
por: Myers JS, et al.
Publicado: (2014)

Comparative Study Between the Efficacy of Microneedling Combined with Trichloroacetic Acid Versus Microneedling with Tacrolimus in the Treatment of Stable Vitiligo
por: Rofaida Elnokaly, et al.
Publicado: (2021)

Genetic Polymorphisms Affecting Tacrolimus Metabolism and the Relationship to Post-Transplant Outcomes in Kidney Transplant Recipients
por: Cheng F, et al.
Publicado: (2021)

Whole-transcriptome sequencing reveals a vernalization-related ceRNA regulatory network in chinese cabbage (Brassica campestris L. ssp. pekinensis)
por: Fengyan Shi, et al.
Publicado: (2021)

Combine therapy as a modern approach to treatment of allergic rhinitis
por: Alexander V. Emelyanov
Publicado: (2021)

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events
por: Tsumura T, et al.
Publicado: (2012)

Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice
por: Pillunat LE, et al.
Publicado: (2016)

Bimatoprost ophthalmic solution 0.03% lowered intraocularpressure of normal-tension glaucoma with minimal adverse events [Corrigendum]
por: Tsumura T, et al.
Publicado: (2013)

Effects of nanoparticles with hydrotropic nicotinamide on tacrolimus: permeability through psoriatic skin and antipsoriatic and antiproliferative activities
por: Wan T, et al.
Publicado: (2017)